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Abstract: The microRNAs (miRNAs) are a class of small, 20–22 nucleotides in length, 
endogenously expressed noncoding RNAs that regulate multiple targets posttranscriptionally. 
Interestingly, miRNAs have emerged as regulators of most physiological and pathological 
processes, including metastatic tumor progression, in part by controlling a reversible process 
called epithelial-to-mesenchymal transition (EMT). The activation of EMT increases the 
migratory and invasive properties fundamental for tumor cell spread while activation of the 
reverse mesenchymal-to-epithelial transition is required for metastasis outgrowth. The EMT 
triggering leads to the activation of a core of transcription factors (EMT-TFs) – SNAIL1/
SNAIL2, bHLH (E47, E2-2, and TWIST1/TWIST2), and ZEB1/ZEB2 – that act as E-cadherin 
repressors and, ultimately, coordinate EMT. Recent evidence indicates that several miRNAs 
regulate the expression of EMT-TFs or EMT-activating signaling pathways. Interestingly, some 
miRNAs and EMT-TFs form tightly interconnected negative feedback loops that control epithe-
lial cell plasticity, providing self-reinforcing signals and robustness to maintain the epithelial 
or mesenchymal cell status. Among the most significant feedback loops, we focus on the ZEB/
miR-200 and the SNAIL1/miR-34 networks that hold a clear impact in the regulation of the 
epithelial-mesenchymal state. Recent insights into the p53 modulation of the EMT-TF/miRNA 
loops and epigenetic regulatory mechanisms in the context of metastasis dissemination will also 
be discussed. Understanding the regulation of EMT by miRNAs opens new avenues for the 
diagnosis and prognosis of tumors and identifies potential therapeutic targets that might help to 
negatively impact on metastasis dissemination and increasing patient survival.
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miRNAs: an overview in cancer
The microRNAs (miRNAs) are small noncoding RNA molecules of 20–22 nucle-
otides (nt) which modulate gene expression posttranscriptionally, binding specific 
sequences present mostly in the 3′ untranslated region (3′ UTR) of target messenger 
RNAs (mRNAs). To date, approximately 700 human miRNAs have been identified, 
and it is estimated that more than 30% of the global mRNA expression is regulated 
by the miRNAs.1 The miRNAs are either localized within introns, sharing promoter 
regulation with the host gene, or endowed with their own independent promoters and 
transcriptional  regulation.  Remarkably, miRNAs are frequently organized in clusters, 
containing several  miRNAs in tandem and found to map to all human chromosomes, 
with the exception of the Y chromosome.2
From miRNA synthesis to the generation of an active RNA-induced silencing 
complex (RISC), miRNAs are subjected to various maturation processes. Briefly, RNA 
Cancer Management and Research 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
206
Díaz-López et al
polymerase II transcribes a long miRNA proprecursor 
in the nucleus, termed primary miRNA (pri-miRNA), of 
several hundred nt and containing a 5′ prime cap (5′ cap) 
and a 3′ poly (A) tail end. This primary precursor is then 
processed by the ribonuclease III Drosha that releases a 
miRNA precursor (pre-miRNA) of approximately 70–80 nt 
that presents a RNA hairpin loop structure. Later, the pre-
miRNA is actively exported by exportin-5 to the cytoplasm 
where it is cleaved by the Dicer complex, removing the 
loop region, and delivering the usually 22 nt mature double-
stranded miRNA. One of the RNA strands is then bound 
by the argonaute protein, resulting in the miRNA-induced 
silencing complex (miRISC) which specifically binds to the 
3′ UTR of mRNA targets.3,4
The specificity of the miRNA-RISC complex is provided 
by the seed – a sequence of 2–8 nt in the miRNA – that rec-
ognizes a complementary sequence in the 3′ UTR of target 
mRNAs. Interestingly, miRNAs use different mechanisms 
to control the mRNA expression. A near-perfect match of 
the seed and the 3′ UTR mRNA sequence leads to mRNA 
degradation; whereas, partial complementation results in 
reduced expression by either mRNA removal or translation 
impairment.3,5 Thus, a single miRNA might affect the expres-
sion of several mRNA targets, even within the same signal-
ing pathway, and simultaneously control diverse biological 
processes, including differentiation, proliferation, migration, 
or cell survival.3–5
One of the first insights into the potential deregulation 
of miRNAs in cancer was the finding by Calin et al6 in 
2004, which showed that approximately one-half of total 
miRNAs are located at fragile sites or in the cancer suscep-
tibility loci. Indeed, genomic amplification, chromosomal 
deletion, point mutation, and aberrant promoter methyla-
tion are the main strategies used by cancer cells to gain or 
lose miRNA  function.4,7 The deregulation of miR-15 and 
miR-16 expression found in chronic lymphocytic leukemia 
was the original evidence for the miRNA implication in 
cancer biogenesis.8 From that first report, an increasing 
number of miRNAs associated with cancer (also called 
oncomiRs) have been reported with pro- or antitumoral 
activities. Intriguingly, several miRNAs have either pro- or 
antitumoral properties, depending on the tumor context. In 
this sense, miR-29 operates as a tumor suppressor in lung 
tumors; whereas, in breast cancer, it bears an oncogenic 
role.9,10 Another example is miR-26, which has been found 
amplified in gliomas,11 while its overexpression induces 
either apoptosis in hepatocellular carcinoma12 or metastasis 
in lung cancer cells.13
Epithelial-to-mesenchymal 
transition in cancer
Cancer constitutes a conglomerate of diseases characterized 
by the loss of growth control and cell dissemination. To 
spread, epithelial tumor cells take advantage of a reversible 
developmental process called epithelial-to-mesenchymal 
transition (EMT) to favor cell migration and invasiveness. 
Once they reach their new niche, they activate the reverse 
 program – mesenchymal-to-epithelial transition (MET) – 
to form macrometastasis.14–17 Intermediate states between 
epithelial and mesenchymal phenotypes are presently con-
sidered to exist during the metastatic cascade,18,19 implying 
that epithelial tumor cells are endowed with a high degree of 
epithelial plasticity that needs to be dynamically regulated 
and finely tuned during tumor progression and metastasis.15 
Epithelial cells are tightly adjoined cells through special-
ized membrane structures: tight  junctions; desmosomes; 
and adherens junctions that constrain cell movement and 
detachment from the epithelial layer. Up to 90% of human 
tumors are carcinomas, which originate from the differenti-
ated epithelium and are susceptible to suffer an EMT process 
within certain tumor subpopulations in response to external 
cues.19–21 The hallmarks of the EMT program are the loss 
of E-cadherin and apical–basal cell polarity, accompanied 
by the gain of mesenchymal characteristics, including the 
acquisition of cell migration and invasion abilities, as well 
as an increased expression of mesenchymal markers, such 
as vimentin, fibronectin, and N-cadherin.17 The molecular 
and cellular mechanisms underlying an EMT are complex 
and can be initiated by multiple extracellular signals that 
finally activate transcription factors, miRNAs, and/or differ-
ent signaling pathways, depending on the physiological or 
pathological contexts. The reverse MET process might be, 
therefore, promoted by blocking the action of the factors and 
signaling pathways that activate EMT.22,23
EMT can be induced by several signaling pathways, 
including transforming growth factor beta (TGF-β), Notch 
and Wnt, among others that converge in the expression of 
a plethora of E-cadherin transcriptional repressors that also 
act as EMT inducers (EMT-TFs).
The EMT-TFs’ core is integrated by members of the 
SNAIL (SNAIL1/SNAIL2), basic helix-loop-helix (bHLH) 
(E47, E2-2, and TWIST1/TWIST2) and ZEB (ZEB1/ZEB2) 
families.16 Several of these EMT-TFs are thereby considered 
EMT drivers, and their expression is directly correlated with 
poor outcome.16,17,21 EMT-TFs from the SNAIL, ZEB, and 
TWIST families govern EMT through a complex EMT-TF 
network, which entails a strong transcriptional control 
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of EMT. However, there is growing evidence that at least 
three additional regulatory levels solidly support the EMT/
MET programs in parallel – miRNA expression, differential 
splicing, and translational and posttranslational control – that 
affect localization and protein stability.14,17,18 In this review, 
we will discuss the most relevant recent findings concerning 
epithelial plasticity regulation by miRNA expression.
It is well -known that the miRNAs regulate a plethora of 
cancer-related pathways, such as cell cycle and proliferation, 
senescence, DNA damage response, apoptosis, and autophagy, 
among others. An increasing number of reports indicate that 
several miRNAs are deregulated in primary tumors compared 
to normal tissue, with some of them being associated to 
metastasis.24 Noticeably, during the last years, the implica-
tion of a growing number of miRNAs in the regulation of 
EMT-TFs or EMT-related pathways has been observed in 
several human tumor contexts (Table 1). Interestingly, poorly 
differentiated carcinomas present an overall decrease of total 
miRNA expression, suggesting a role for the miRNAs in 
the regulation of different mechanisms governing epithelial 
plasticity.25 Targeting the EMT-TFs’ modulators or the EMT-
TFs themselves, pivotal proteins implicated in invasion and 
migration, and/or regulatory enzymes involved in miRNA 
biosynthesis constitutes the most common mechanism used 
by the miRNAs to regulate epithelial plasticity and, hence, 
promote or inhibit metastatic tumor progression.
miRNA regulation  
of epithelial plasticity
As mentioned, a hallmark of EMT is E-cadherin loss, 
mainly due to its transcriptional repression by EMT-TFs. 
A few  miRNAs have been involved in the direct regulation 
of E-cadherin expression. An example is miR-9, which 
directly targets the E-cadherin gene in breast cancer cells.26 
Interestingly, miR-9 is upregulated by MYC. Its expression 
is correlated with MYCN amplification, tumor grade, and 
the metastasis status in breast cancer patients.26 Conversely, 
miR-9 acts as a tumor suppressor in melanoma cells by 
targeting the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB)-SNAIL1 pathway, thus upregu-
lating the E-cadherin expression.27 Furthermore, additional 
activities of the miR-9 have been described, including its 
secretion by the tumor cells within microvesicles to promote 
endothelial cell migration and angiogenesis,28 revealing the 
complexity of miRNA activities depending on cell context 
and tumor type.
Another mechanism to control epithelial plasticity is 
regulating those pathways controlling EMT. Recently, several 
miRNAs that directly impinge on the regulation of EMT-
TFs have been described; some of them operate in double 
negative feedback loops that contribute to maintain the 
epithelial or mesenchymal states29–31 (Figure 1). In addition, 
these EMT-regulatory miRNA networks can be controlled 
by EMT-inducing signals, like TGF-β signaling, and/or 
by p53, implementing additional levels of regulation and 
providing robustness to the system. In this review, we will 
discuss the most relevant miRNA-EMT-TF networks dis-
covered to date.
ZeB/miR-200 feedback loop
The two members of the zinc finger E-box-binding homeobox 
(ZEB family), ZEB1/δEF1, and ZEB2/SIP1, are among the 
first described EMT-TFs32,33 and have emerged as the better-
studied EMT-TFs subject to miRNA regulation because their 
expression is associated with poor prognosis in several tumor 
types.16,34–36 ZEB1 has been found upregulated in metaplastic 
breast carcinomas37 as well as in the sarcomatous element 
of endometrial carcinosarcomas, an aggressive neoplasia 
with a biphasic histology of carcinomatous and sarcoma-
tous components considered an example of complete EMT 
in vivo.38,39 Moreover, ZEB1 silencing in a colorectal cancer 
xenograft model blocks metastasis.40 One of the first pieces of 
Table 1 Selected miRNAs implicated in metastatic progression 
and their eMT-related known targets
miRNA Cancer type Target References
miR-1 Prostate SNAIL2 71
miR-9 Breast CDH1 26,113
miR-29 Prostate, breast,  
colorectal
SNAIL1, LOX, MMP2,  
MMP9, VEGFA
62,103, 
114,115
miR-30 Lung SNAIL1 116
miR-34 Breast, lung, colon,  
prostate
SNAIL1, NOTCH4,  
CD44, FRA-1,  
SIRT1, BCL2, NMYC
60,90,117
miR-103/ 
miR-107
Breast DICER 97
miR-141 Prostate, colorectal,  
endometrial  
carcinosarcoma
ZEB1/ZEB2 39,101,118
miR-200 Pancreatic, colorectal,  
endometrial  
carcinosarcoma
ZEB1/ZEB2, SEC23A,  
BMI1
39,43–45,53
miR-10B Breast, melanoma HOXD10 84,119
miR-192 Liver ZEB2 120
miR-203 Prostate, breast ZEB2, BMI1, RUNX2,  
SNAIL2
73,121
miR-205 esophageal ZEB1/ZEB2 44,122
LeT-7 Breast endometrial 
carcinoma
HMGA2, BACH1 69,70,123
Abbreviations: miRNA, microRNA; eMT, epithelial-to-mesenchymal transition; 
LeT-7, the lethal-7 family of miRNAs.
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evidence  confirming a functional role for the miRNA control 
of epithelial plasticity is the regulation of ZEB proteins by 
the miR-200 family (miR-200f) and miR-20541 (Figure 1). 
The miR-200f is composed of five members located in two 
polycistronic pri-miRNA loci on chromosome 1 (miR-200b, 
miR-200a, and miR-429) and chromosome 12 (miR-200c 
and miR-141).41
In 2007, Christoffersen et al42 reported for the first time 
the ZEB regulation by miR-200f, identifying nine target 
sites for miR200f and two for miR-205 in the 3′ UTR of 
ZEB2. Shortly after that finding, two reports identified sev-
eral functional targeting sites in both ZEB1/ZEB2.43,44 Park 
et al43 described a significant positive correlation between 
high E-cadherin/low vimentin expression and miR-200f 
levels after miRNA expression profile analyses of a cell 
panel including 60 epithelial and mesenchymal cell lines 
from the National Cancer Institute. Ectopic expression of 
miR-200f in colorectal HCT-116 cells or their silencing in 
breast carcinoma MDA-MB-231 significantly affected ZEB1 
expression, sustaining a nontissue specific regulation.43
Similar results were found by Gregory et al44 in 
 Madin-Darby canine kidney cells after TGF-β-mediated 
EMT. Furthermore, both Burk et al45 and Bracken et al46 
simultaneously demonstrated that ZEB1 silencing in mesen-
chymal cancer cells induced miR-200f expression, resulting 
in a negative feedback loop. Remarkably, the ZEB1-mediated 
repression was leaded by its direct binding to the E-box sites 
present upstream of miR-200c/miR-14145 or miR-200b/miR-
200a/miR-429 promoters.46
In addition to targeting ZEB1/ZEB2, miR-200f regulates 
the expression of diverse stemness-related genes, such as 
CD44, BMI1, and c-MYC. Conversely, ZEB1 represses 
miR-183 and miR-203 which, in turn, target BMI1 and 
other stemness factors, such as SOX2 and KLF4,47 which 
support previous studies that showed that EMT confers cell 
stemness properties.48,49 Importantly, the EMT-stemness 
association is also found in vivo in basal-like breast tumors, 
a subtype of breast cancer associated with poor differentiation 
grade, enriched in numerous EMT, and stemness markers.50 
 Interestingly, in some cellular contexts, the miR-200f/ZEB1 
feedback loop can be maintained and reinforced by autocrine 
secretion of TGF-β, thus contributing to the maintenance of 
the mesenchymal phenotype.51 Additionally, in cancer stem 
cells, E-cadherin is also an indirect target of miR200f through 
SUZ12, a component of the PRC2 complex, thus resulting in 
the epigenetic repression of E-cadherin and the upregulation 
of ZEB1/ZEB2.52
Aside from the established double feedback loop, 
 miR-200f also acts in a ZEB1/ZEB2 independent manner, 
being associated with the regulation of Sec23a, a modulator of 
miR-10b
miR-30
miR-203
miR-205
miR-192
miR-203
miR-204
miR-1
miR-9
miR-138
miR-130
miR-183-96-182
miR-22
miR-200f
miR-34
miR-29
E-cadherin
TET
Epigenetic
SNAIL 1 SNAIL 2
TWIST 1
E2-2
ZEBs
E47
ID1
Figure 1 miRNA and eMT-TF regulatory networks controlling epithelial plasticity.
Notes: eMT-TFs positively regulate the expression of other eMT-TFs in a tightly hierarchical regulated network. Different miRNAs negatively regulate core eMT-TFs, and 
some of them orchestrate negative feedback loops reinforcing the system. epigenetic regulation of some miRNAs provides additional robustness to the eMT program.
Abbreviations: miRNA, microRNA; TeT, ten-eleven translocation; eMT, epithelial-to-mesenchymal transition; TF, transcription factor.
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the secretome.53 Targeting Sec23a, a coat protein  complex II 
(COPII) vesicle component, resulted in decreased  secretion of 
the metastasis suppressive factors tubulointerstitial nephritis 
antigen-like 1 (TINAGL1) and insulin-like growth factor 
binding protein 4 (IGFBP4) in 4TO7 cells.53  Moreover, 
 miR-200a suppresses β-cat/Wnt signaling by targeting 
β-catenin. Consequently, miR200a downregulation in some 
tumors, like meningiomas, activates the β-cat/Wnt pathway, 
represses E-cadherin, and promotes tumor growth.54
All these findings support a dual role of miR-200f in the 
tumor progression and the regulation of epithelial plasticity. 
Thus, miR-200f-silencing facilitates early steps of metas-
tasis impacting on EMT control by ZEB1/ZEB2, while its 
upregulation at distal metastasis might promote MET and 
metastatic colonization through Sec23 targeting.53 Interest-
ingly, the tumor suppressor p21 controls miR-200 levels but 
also the miR-183-96-182 cluster, which represses ZEB1, 
SNAIL2, ITGB1, and KLF4 expression in HCT-116 colorectal 
cells.55 However, the biological implication of miR-183-96-
182 in EMT and metastasis remains still unknown, since 
knockdown of individual members of the cluster did not 
affect cell invasion.55
ZEB factors can be regulated by additional miRNAs, 
like miR-19256 or miR-13857 targeting ZEB2, and the 
recently described miR-130 acting on ZEB158 (Figure 1). 
On the other hand, ZEB2 is indirectly regulated by miR-221/
miR-222, which is overexpressed in basal-like breast tumors. 
The miR-221/miR-222 targets the ZEB2-repressor TRPS1, 
a GATA family transcription factor, promoting E-cadherin 
downregulation and increased migration and invasion 
properties.59
SNAiL1 regulation:  
the SNAiL1/miR-34 axis
Similar to the ZEB/miR-200 negative feedback loop, 
SNAIL1, and the miRNAs, the miR-34f (miR-34a, miR-34b, 
and miR-34c) and miR-203, constitute additional epithelial 
plasticity regulatory loops60,61 (Figure 1). Interestingly, 
the seed sequence of miR-34 targets a highly conserved 
3′ UTR sequence present in SNAIL1, SNAIL2, ZEB1, and 
also the stemness factors BMI1, CD44, CD133, and c-MYC. 
 Conversely, SNAIL1 and ZEB1 directly repress the miR-34f60 
and miR-200f promoters,45,46 respectively, providing a tight 
crosstalk between the ZEB/miR-200 and SNAIL1/miR-34 
pathways and adding robustness to the network.
SNAIL1 expression is also controlled by miR-29b, 
miR-30, and by a second negative feedback loop  involving 
miR-20361–63 (Figure 1). Accordingly, the expression of 
miR-29 induces a complete MET and decreases the invasive 
phenotype in the prostate cancer cell line PC3.62 Another 
elegant strategy to silence SNAIL1 expression involves tar-
geting SNAIL1-activation pathways. The lethal-7 (LET-7) 
family is formed by 12 miRNA members located on eight 
different chromosomes in humans. Remarkably similar to 
miR-200, the LET-7 family has no tissue-dependent activity, 
but rather its role is related to the differentiation states of 
the tissue, suggesting that both miRNAs families are central 
differentiation regulators.64 The LET-7 family member levels 
are downregulated in various cancers, including lung, colon, 
ovarian, and gastric carcinomas – as well as melanoma – 
during tumor progression, supporting their central role in 
epithelial plasticity.
Mechanistically, LET-7 acts as a tumor suppressor in humans, 
mainly because it directly binds to the transcripts of multiple 
genes with oncogenic activity, such as RAS, the high mobility 
group (HMG)A2, or BACH1.65 HMGA2, a  chromatin-binding 
protein that integrates the TGF-β response66 is downregulated 
by the LET-7 miRNA family in pancreatic human cells67 or by 
miR-365 in lung adenocarcinoma,68 thus indirectly affecting 
SNAIL1 expression. Importantly, the LET-7 family coordi-
nates other antimetastatic events by repressing H-RAS and 
the  transcription factor BACH1. Both HMGA2 and BACH1 
promote the transcription of proinvasive genes, cell invasion, 
and the metastasis to the bone of breast cancer cells.69,70
SNAiL2 regulation
SNAIL2 is regulated posttranscriptionally by different 
 miRNAs, including miR-1, miR-203, and miR-20471–73 
(Figure 1). In a recent report using a PTEN- and TP53-null 
prostate adenocarcinoma mice model that progresses via 
TGF-β-induced EMT, SNAIL2 was the main driver of EMT 
activation.74 In this model, miR-1 was downregulated by a 
double-negative feedback loop including SNAIL2 and the 
miRNAs  – miR-1 and miR-200b – in a self-reinforcing regu-
latory loop, favoring EMT.71 SNAIL2 is also a direct target 
of miR-20472 and miR-20373 in retinal pigment epithelium 
and breast cancer cells, respectively.
Remarkably, miR-204 acts using a dual mechanism, 
targeting TGFBR2, a TGF-β receptor, but also by the direct 
targeting of SNAIL2.72 On the other hand, the ectopic expres-
sion of miR-203 induces apoptosis and blocks cell cycle 
progression and invasion in breast cancer cell lines mediated, 
at least partially, by SNAIL2 repression.73
All the present findings indicate a tight regulation of 
epithelial plasticity by direct and indirect modulation of 
crucial EMT-TFs. This, together with the interconnection 
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between several core EMT-TFs75–78 (Figure 1), provides robust-
ness to the system as well as the potential to modulate epithelial 
plasticity in response to different environmental cues.
Other miRNAs implicated in metastasis
Some miRNAs are not directly implicated in EMT-TF 
regulation but are relevant for metastatic dissemination, 
either suppressing or promoting metastasis. A significant 
suppressive miRNA is miR-335, which targets SOX4 and 
 Tenascin-C, thus, promoting cancer cell migration,  invasion, 
and  metastasis.79 In the same study, downregulation of 
miR-206 and miR-126 was found to be correlated with 
metastatic relapse in breast cancer patients.  Restoration 
of miR-335 or miR-206 expression in a lung metastatic 
MD-MB231-derived cell line reduces its metastatic 
dissemination.79 Interestingly, the role of miR-126 is linked 
to tumor growth, endothelial recruitment, and metastatic 
initiation by inhibiting the proangiogenic factors: IGFBP2; 
PITPNC1; and MERTK.80 Another example is miR-31, 
a metastasis relapse marker in breast tumors. The miR-31 
targets the prometastatic proteins ITGA5, RdX, and RhoA – 
thus blocking invasion, anoikis resistance, and metastasis.81 
However, miR-31 silencing is observed in other tumor types, 
suggesting that miR-31 pro- or antitumorigenic function 
depends on tumor context.82
On the other hand, overexpression of some miRNAs 
confers prometastatic ability to the tumor cells, like miR-10b, 
which is frequently overexpressed in primary invasive breast 
carcinomas and their metastasis.83,84 However, the mechanism 
of action of this miRNA is not based on targeting the core 
EMT-TFs. The miR-10b is, in fact, induced by the EMT-TF 
TWIST1 (Figure 1), and it is associated with mesenchymal 
features and invasion properties by inhibiting HOXD10, an 
inhibitor of the prometastatic protein ROCK.84 Interestingly, 
miR-106b modulates TWIST1 expression and invasiveness 
in endometrial cancer cells.85 Besides, the overexpression 
of miR-373 and miR-520c confers metastatic capacity to 
breast86 and prostate cancer cells87 by suppressing CD44 
expression.
In melanoma, a highly metastatic tumor,  miR-199a-3p, 
miR-199a-5p, and miR-1908 promote metastatic inva-
sion, angiogenesis, and colonization by targeting the 
apolipoprotein E and the heat shock factor  DNAJA4.88 
Expression of these three miRNAs directly correlates with 
melanoma metastatic outcome. Overexpression of  miR- 30b/
miR-30d also correlates with stage, metastatic potential, 
and reduced overall survival in melanoma patients.89 
 Accordingly, ectopic expression of miR-30b/miR-30d in 
melanoma cells increased their metastatic behavior by a dual 
mechanism – promoting invasion and immunosuppression by 
directly targeting the GalNAc transferase GALNT7.89
miRNA regulation in epithelial 
plasticity and metastasis
The dynamic nature of the EMT and MET processes along 
the metastatic cascade implies a finely tuned, regulated 
control of tumor cell plasticity that can be exerted, at least 
in part, through posttranscriptional modulation of the EMT-
TFs, such as that mediated by miRNAs. The regulation of 
the miRNA expression linked to EMT and metastasis is still 
poorly known. Nevertheless, several mechanisms that have 
started to be exposed during the last years will be discussed 
in this section.
The p53-eMT connection
Numerous recent reports highlight a connection between 
p53 and EMT through the modulation of some miRNAs that 
regulate EMT-TFs in different tumor models. p53 has been 
reported to maintain the epithelial phenotype by enhancing 
miR-34 expression and subsequently repressing SNAIL1. 
Importantly, a mutated form of p53 is unable to increase 
miR-34 expression, shifting the equilibrium toward a mesen-
chymal phenotype in colorectal carcinoma cells.90 A similar 
situation occurs in the endometrial carcinomas, where a 
p53 gain-of-function mutant exerts oncogenic properties by 
transcriptional inhibition of miR-130b, a negative regulator 
of ZEB1. Interestingly, patients with higher levels of miR-
130b survived longer.58
Additionally, p53 indirectly controls EMT by the tran-
scriptional regulation of other miRNAs. AP4, a transcrip-
tion factor recently described as a new EMT inducer,91 
is indirectly regulated by p53 through the expression of 
miR-15a/16-1 in colorectal cancer cells.92 Ectopic expres-
sion of miR-15/miR-16-1 suppresses lung metastatic 
colonization in a xenograft model. Conversely, AP4 inhibits 
miR-15/miR-16-1  expression defining a novel negative 
regulatory loop92 (Figure 2). Wild type p53 also controls 
EMT and stemness properties in the prostate cancer cell 
line PC-3, at least in part, by enhancing the expression 
of miR-145. Accordingly, anti-miR-145 partially reverts 
this phenotype.93 Collectively, all these findings define 
a new link between chromosome stability, p53, miRNA 
expression, cell differentiation, and epithelial plasticity 
that can be potentially used by cancer cells for the initial 
stages of metastatic tumor progression, such as invasion 
or intravasation.
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epigenetic regulation of miRNAs  
involved in epithelial plasticity
Since the EMT-TF expression has to be regulated by dif-
ferent miRNAs in a dynamic fashion during the metastatic 
cascade, CpG miRNA promoter hypermethylation has 
emerged as a novel mechanism to increase the mesenchymal 
characteristics of tumor cells due to specific miRNA repres-
sion. For example, CpG oligonucleotide hypermethylation of 
the miR-34 promoter is found in prostate tumors (80%) and in 
melanoma (63%); it is also present in many cell lines derived 
from breast, colon, lung, and other types of tumors.94,95 The 
miR-203, which targets SNAIL2, is also hypermethylated in 
several tumors, including hepatocellular, prostate, and breast 
carcinoma.73
Epigenetic regulation of the miR-200 family and its rela-
tionship with aggressiveness and chemoresistant behavior 
have been established in different cancer cell types, including 
nonsmall cell lung carcinomas, colon, breast carcinomas, as 
well as endometrial carcinosarcomas.39,95,96 Interestingly, the 
hypermethylation rate of the miR-200 loci is related to the 
breast cancer subtype and metastasis outcome. Promoter 
analysis in 93 breast cancers has identified the presence 
of a novel CpG promoter region in the miR-200b cluster, 
mapped 2 kb upstream of the 5′ stem loop region, whose 
hypermethylation was associated with the loss of either 
estrogen or progesterone receptors, while hypermethyla-
tion of the upstream promoter is associated with lymph 
node metastasis.96 In addition, a direct correlation between 
miR-200c-141 loci expression and hypermethylation has 
been found in endometrial carcinosarcomas.39 In fact, the 
hypermethylation of this locus seems to be a surrogate 
marker to differentiate endometrial carcinosarcomas versus 
carcinomas.39  Hypermethylation of the miR-200f has also 
been observed in colorectal tumors.95 Microdissection of 
human primary colorectal samples showed that normal epi-
thelial colon mucosa crypts and stroma (mesenchyme) bear 
unmethylated and methylated miR-200f promoters, respec-
tively.  Colorectal tumors undergo selective miR-200 hyper-
methylation, sustaining the association between methylation 
and differentiation status.95 Interestingly, the expression of 
miR-22 is correlated with miR-200 downregulation and 
poor outcome in breast cancer patients.96 Mechanistically, 
miR-22 triggers EMT, enhancing invasiveness, and promot-
ing metastasis in mice xenografts, through the targeting of 
the ten-eleven translocation (TET) family of methylcyto-
sine dioxygenases, and is implicated in the  inhibition of 
p53
miR-34 miR-15a/16-1
miR-200f
miR-205
AP4SNAIL1 ZEBs
miR-130 miR-145
EMT
Figure 2 The p53 modulation of miRNA-eMT-TF networks.
Notes: The p53 positively regulates several miRNAs that downregulate different eMT-TFs or act by indirect mechanism on eMT regulation (ie, miR-145). Most of the p53-
regulated miRNAs are involved in double-negative regulatory loops.
Abbreviations: miRNA, microRNA; eMT, epithelial-to-mesenchymal transition; TF, transcription factors.
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miR-200 promoter demethylation, thereby inducing dedif-
ferentiation90 (Figure 1).
Additional miRNA regulatory 
mechanisms
The components of the miRNA processing machinery have 
also been involved in cancer progression, resulting in an 
overall decrease of mature miRNAs. Interestingly, high 
levels of miR-103/miR-107 are associated with reduced 
expression of Dicer and metastasis as well as with poor 
outcome in breast cancer patients.97 Mechanistically, the 
overexpression of miR-107 in MB-MDA-231 or SUM149 
breast carcinoma cells confers migratory capacities in vitro 
and empowers metastatic dissemination in vivo by foster-
ing EMT through the downregulation of miR-200 levels.97 
Reduced Dicer expression was also found in nonsmall cell 
lung carcinomas and in ovarian cancer, sustaining a more 
complex mechanism in tumor progression.98,99 Moreover, the 
tumor suppressor TP53 also affects the miRNA biogenesis 
machinery facilitating the processing of pri-miRNAs to pre-
miRNAs through its interaction with the Drosha processing 
complex,100 revealing a wide control regulation by p53 apart 
from that relying on each specific miRNA’s regulation already 
discussed (Figure 2).
Potential clinical applications
One of the deleterious effects of tumor progression is the 
formation of distant tumors or metastasis. In fact, metastases 
are the main cause of cancer death. Besides understanding 
the functional miRNAs implicated in cancer, their analyses 
in cancer patients open new avenues for diagnosis, prognosis, 
and treatment in oncology. Although we are now beginning 
to understand how the miRNA regulates epithelial plasticity 
and metastasis, more efforts have to be made to transfer these 
findings into the clinic. Here, we will describe the different 
approaches found from miRNA analysis that might be applied 
for EMT-related miRNAs into the clinics.
miRNAs as predictive markers
The miRNAs can be found in biological fluids, including: 
blood; urine; tears; breast milk; bronchial lavage; colostrum; 
seminal; amniotic; pleural; peritoneal; and cerebrospinal 
 fluids. Moreover, endogenous serum miRNAs are very stable, 
even after boiling, freeze–thaw cycles, or low or high pH 
conditions, thus providing an easy substrate for detection and 
analysis. The quantitative polymerase chain reaction detec-
tion is the most feasible and cost-effective method to detect 
miRNA expression; however, next generation sequencing 
might be used as an alternative method, overtaking the use 
of normalizing miRNA expression levels.
Expression levels of circulating miRNA in plasma can 
be used to discriminate patients with different outcomes. 
 Accordingly, serum levels of miR-141 can distinguish 
between healthy subjects and patients with prostate cancer.101 
The sensitivity of the approach can be highly improved using 
more than a single miRNA.102 In colorectal cancer patients, 
elevated mir-92a and mir-29a levels in plasma are useful 
biomarkers of the disease.103 Importantly, the quantitative 
polymerase chain reaction analyses in the blood of miR-10b, 
miR-34, and miR-155 – some of them involved in EMT 
regulation and/or metastasis – allows the discrimination 
between breast cancer metastasis patients from the healthy 
controls,104 and miRNA expression profiles can be a classifier 
of responder versus nonresponder patients for chemotherapy 
in colon cancers.105
Many miRNAs have been correlated with tumor patient 
outcome.3,4,24 Tumors with low expression levels of miR-335 
and miR-126 have more probability to develop  metastasis 
than tumors with higher expression.79 The miR-210, 
a  hypoxia-induced miRNA, is an independent prognostic 
marker in breast cancer and shows inverse correlation 
with disease-free and overall survival outcomes.106 The 
well- studied oncomiR miR-21 has been considered a poor 
prognosis biomarker in breast, squamous cell carcinoma, 
astrocytoma, and gastric cancer.107 Related to epithelial plas-
ticity, DNA methylation of the miR-200c-141 locus might be 
a useful surrogate marker of endometrial carcinosarcomas.39 
The expression of miR-200f and CpG methylation status 
of the miR-200c-141 locus is able to discriminate breast 
cancer subtypes.37 Indeed, metaplastic breast tumors with 
sarcomatoid differentiation present the higher downregula-
tion of miR-200f and hypermethylation of the miR-200c-141 
locus compared with other cancer types. Moreover, basal-like 
and HER2 positive breast tumors exhibited lower miR-200f 
expression than estrogen receptor positive tumors.37
miRNAs: a promising therapeutic tool
The miRNAs could potentially be used as therapeutic tools 
in cancer. Depending on the protumoral or antitumoral 
properties, different strategies based on blocking miRNA 
function or specific miRNA delivery to the tumor cells can 
be used. At present, different preclinical approaches directed 
to block miRNAs are being developed, which include anti-
miRNA oligonucleotides, miRNA sponges, miRNA masks 
(target protectors), and small molecule inhibitors.108 The 
miRNA sponges are synthetic miRNAs that contain multiple 
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 tandem-binding sites of the endogenous miRNA. They harbor 
the seed sequence, allowing the inhibition of the complete 
family of related miRNAs. The miRNA masks are single-
stranded 2-O-methyl modified antisense oligonucleotides 
that lose their repression activity, but they maintain full 
complementarity to the predicted miRNA-binding sites. 
Treatment of melanoma cells with locked nucleic acids tar-
geting miR-1908, miR-199a-5p, and miR-199a-3p inhibits 
metastasis to multiple organs, and the therapeutic delivery of 
these locked nucleic acids suppresses melanoma metastasis.88 
Similar studies have been developed by inhibiting miR-182 
to treat metastasis in melanoma mouse models.109
However, the delivery of tumor suppressor miRNAs is 
a potential therapeutic application, in particular to promote 
the differentiation of cancer stem cells to increase their 
sensitivity to traditional therapies. Nevertheless, the deliv-
ery of miRNA to solid tumors is technically a challenging 
issue.  Different strategies to deliver miRNAs to tumor cells 
are being  developed based on synthetic miRNA precursors, 
lentiviral and adenovirus vectors, or nanoparticles.110 For 
example, miR-26 adenovirus delivery arrests cell cycle pro-
gression and induces tumor specific apoptosis in liver cells.12 
However, actual strategies are limited by high toxicity and 
the lack of cell specificity of the delivery.
The miRNAs might also be useful as coadjuvant thera-
pies in cancer treatment. For example, the miR-21  inhibition 
sensitizes breast cancer cells to the chemotherapeutic 
drugs, Topotecan and Taxol.111 The expression of miR-205 
in SkBR3 breast cancer cells targets HER3, leading to an 
increased response to the tyrosine kinase inhibitors gefitinib 
and lapatinib.112 Although these data were obtained in vitro 
and need to be reevaluated in vivo, miRNA targeting might 
represent a promising coadjuvant strategy for metastatic 
cancer patients.
Conclusion
To acquire a migratory/invasive phenotype for metastatic 
progression, tumor cells activate the developmental EMT 
program. Remarkably, the activation of an EMT program 
must be temporarily limited and coupled to the reversible 
program, MET, for macrometastasis formation. Because 
epithelial plasticity must be finely regulated along the 
metastatic cascade, miRNAs have emerged as critical regu-
lators necessary for metastatic progression. Indeed, these 
small RNA sequences use different mechanisms to regulate 
epithelial plasticity, such as targeting different signaling 
pathways, EMT-TFs, and/or their targets, or the proper 
miRNA  maturation machinery. The presence of double 
 negative feedback loops defines flexible and efficient con-
trol of EMT and MET processes providing self-reinforcing 
signals to maintain the epithelial or the mesenchymal status 
of the cell. The redundancy observed in the targeting of 
different EMT related genes would contribute to the stabil-
ity of the regulation during physiological or pathological 
events.  Consequently, modifying a single miRNA might 
activate or inactivate different pathways required for tumor 
cells to survive and/or invade during the metastatic cascade. 
 Understanding the different strategies employed by tumor 
cells to switch on/off EMT will challenge oncologists’ efforts 
for the next years, providing new avenues for early diagnosis, 
prognosis, and the treatment of human tumors.
Acknowledgments
AC is funded by grants of the Spanish Ministry of Economy 
and Competitiveness, formerly Innovation and Sciences, 
(SAF2010-21143; Consolider-Ingenio CSD2007-00017) 
and Association for International Cancer Research (grant 
12-1057). GMB is funded by SAF2010-20175, AECC-2011 
and Instituto de Salud Carlos III (ISCIII) PI13/00132. GMB 
and AC are funded by the Community of Madrid (S2010/
BMD-2303) and the Instituto de Salud Carlos III (RETIC-
RD12/0036/0007). ADL is a postdoctoral researcher funded 
by the Sara Borrell program (ISCIII).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked 
by adenosines, indicates that thousands of human genes are microRNA 
targets. Cell. 2005;120(1):15–20.
2. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA 
annotation and deep-sequencing data. Nucleic Acids Res. 2011; 
39(Database issue):D152–D157.
3. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation 
and an emerging reciprocal relationship. Nat Rev Genet. 2012;13(4): 
271–282.
4. Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in 
cancer. Nat Rev Cancer. 2006;6(4):259–269.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. 
Cell. 2009;136(2):215–233.
6. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes 
are frequently located at fragile sites and genomic regions involved in 
cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.
7. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol 
Rev. 2011;91(3):827–887.
8. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and 
down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in 
chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24): 
15524–15529.
9. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts 
aberrant methylation in lung cancer by targeting DNA methyltransferases 
3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805–15810.
Cancer Management and Research 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
214
Díaz-López et al
 10. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses 
tristetraprolin, which is a regulator of epithelial polarity and metastasis. 
EMBO Rep. 2009;10(4):400–405.
 11. Huse JT, Brennan C, Hambardzumyan D, et al. The PTEN-regulating 
microRNA miR-26a is amplified in high-grade glioma and facilitates 
gliomagenesis in vivo. Genes Dev. 2009;23(11):1327–1337.
 12. Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA 
delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 
2009;137(6):1005–1017.
 13. Liu B, Wu X, Liu B, et al. MiR-26a enhances metastasis potential of 
lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys 
Acta. 2012;1822(11):1692–1704.
 14. De Craene B, Berx G. Regulatory networks defining EMT during cancer 
initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
 15. Nieto MA. Epithelial plasticity: a common theme in embryonic and 
cancer cells. Science. 2013;342(6159):1234850.
 16. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype? Nat Rev 
Cancer. 2007;7(6):415–428.
 17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal 
transitions in development and disease. Cell. 2009;139(5):871–890.
 18. Nieto MA, Cano A. The epithelial-mesenchymal transition under 
control: global programs to regulate epithelial plasticity. Semin Cancer 
Biol. 2012;22(5–6):361–368.
 19. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal 
plasticity in cancer. Nat Med. 2013;19(11):1438–1449.
 20. Scheel C, Onder T, Karnoub A, Weinberg RA. Adaptation versus 
selection: the origins of metastatic behavior. Cancer Res. 2007;67(24): 
11476–11479.
 21. Polyak K, Weinberg RA. Transitions between epithelial and 
 mesenchymal states: acquisition of malignant and stem cell traits. Nat 
Rev Cancer. 2009;9(4):265–273.
 22. Ocaña OH, Córcoles R, Fabra A, et al. Metastatic colonization requires 
the repression of the epithelial-mesenchymal transition inducer Prrx1. 
Cancer Cell. 2012;22(6):709–724.
 23. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal 
 regulation of epithelial-mesenchymal transition is essential for squamous 
cell carcinoma metastasis. Cancer Cell. 2012;22(6):725–736.
 24. Pencheva N, Tavazoie SF. Control of metastatic progression by 
microRNA regulatory networks. Nat Cell Biol. 2013;15(6):546–554.
 25. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify 
human cancers. Nature. 2005;435(7043):834–838.
 26. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated 
microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 
2010;12(3):247–256.
 27. Liu S, Kumar SM, Lu H, et al. MicroRNA-9 up-regulates E-cadherin 
through inhibition of NF-kappaB1-Snail1 pathway in melanoma. 
J Pathol. 2012;226(1):61–72.
 28. Zhuang G, Wu X, Jiang Z, et al. Tumour-secreted miR-9 promotes 
endothelial cell migration and angiogenesis by activating the 
JAK-STAT pathway. EMBO J. 2012;31(17):3513–3523.
 29. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop – a motor of 
cellular plasticity in development and cancer? EMBO Rep. 2010;11(9): 
670–677.
 30. Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the 
crossroads of signal transduction in cancer. Int J Cancer. 2013;132(4): 
745–754.
 31. Brabletz T. MiR-34 and SNAIL: another double-negative feedback 
loop controlling cellular plasticity/EMT governed by p53. Cell Cycle. 
2012;11(2):215–216.
 32. Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding 
zinc finger protein SIP1 downregulates E-cadherin and induces  invasion. 
Mol Cell. 2001;7(6):1267–1278.
 33. Eger A, Aigner K, Sonderegger S, et al. DeltaEF1 is a transcriptional 
repressor of E-cadherin and regulates epithelial plasticity in breast 
cancer cells. Oncogene. 2005;24(14):2375–2385.
 34. Sánchez-Tilló E, Liu Y, de Barrios O, et al. EMT-activating  transcription 
factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life 
Sci. 2012;69(20):3429–3456.
 35. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and 
ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 
2009;28(1–2):151–166.
 36. Siebzehnrubl FA, Silver DJ, Tugertimur B, et al. The ZEB1 pathway 
links glioblastoma initiation, invasion and chemoresistance. EMBO 
Mol Med. 2013;5(8):1196–1212.
 37. Castilla MÁ, Díaz-Martín J, Sarrió D, et al. MicroRNA-200 fam-
ily modulation in distinct breast cancer phenotypes. PLoS One. 
2012;7(10):e47709.
 38. Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, et al. Micro-RNA 
signature of the epithelial-mesenchymal transition in endometrial 
carcinosarcoma. J Pathol. 2011;223(1):72–80.
 39. Díaz-Martín J, Díaz-López A, Moreno-Bueno G, et al. A core 
microRNA signature associated with inducers of the epithelial-to-
mesenchymal transition. J Pathol. 2014;232(3):319–329.
 40. Spaderna S, Schmalhofer O, Wahlbuhl M, et al. The transcriptional 
repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. 
Cancer Res. 2008;68(2):537–544.
 41. Cano A, Nieto MA. Non-coding RNAs take centre stage in epithelial-
to-mesenchymal transition. Trends Cell Biol. 2008;18(8):357–359.
 42. Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. 
miR-200b mediates post-transcriptional repression of ZFHX1B. RNA. 
2007;13(8):1172–1178.
 43. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family  determines 
the epithelial phenotype of cancer cells by targeting the E-cadherin 
repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894–907.
 44. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and 
miR-205 regulate epithelial to mesenchymal transition by targeting 
ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
 45. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between 
ZEB1 and members of the miR-200 family promotes EMT and invasion 
in cancer cells. EMBO Rep. 2008;9(6):582–589.
 46. Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative 
feedback loop between ZEB1-SIP1 and the microRNA-200 family 
regulates epithelial-mesenchymal transition. Cancer Res. 2008;68(19): 
7846–7854.
 47. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 
 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. 
Nat Cell Biol. 2009;11(12):1487–1495.
 48. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transi-
tion generates cells with properties of stem cells. Cell. 2008;133(4): 
704–715.
 49. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. 
Generation of breast cancer stem cells through epithelial-mesenchymal 
transition. PLoS One. 2008;3(8):e2888.
 50. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, 
Palacios J. Epithelial-mesenchymal transition in breast cancer relates 
to the basal-like phenotype. Cancer Res. 2008;68(4):989–997.
 51. Gregory PA, Bracken CP, Smith E, et al. An autocrine TGF-beta/ZEB/
miR-200 signaling network regulates establishment and maintenance 
of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22(10): 
1686–1698.
 52. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, 
Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-
mediated repression required for the formation and maintenance of 
cancer stem cells. Mol Cell. 2010;39(5):761–772.
 53. Korpal M, Ell BJ, Buffa FM, et al. Direct targeting of Sec23a by 
miR-200s influences cancer cell secretome and promotes metastatic 
colonization. Nat Med. 2011;17(9):1101–1108.
 54. Saydam O, Shen Y, Würdinger T, et al. Downregulated microRNA-200a 
in meningiomas promotes tumor growth by reducing E-cadherin and 
activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol. 
2009;29(21):5923–5940.
Cancer Management and Research 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
215
microRNAs in epithelial plasticity regulation
 55. Li XL, Hara T, Choi Y, et al. A p21-ZEB1 Complex Inhibits Epithelial-
Mesenchymal Transition through the MicroRNA 183-96-182 Cluster. 
Mol Cell Biol. 2014;34(3):533–550.
 56. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney 
glomeruli and its function in TGF-beta-induced collagen expression via 
inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104(9): 
3432–3437.
 57. Liu X, Wang C, Chen Z, et al. MicroRNA-138 suppresses epithelial-
 mesenchymal transition in squamous cell carcinoma cell lines. 
Biochem J. 2011;440(1):23–31.
 58. Dong P, Karaayvaz M, Jia N, et al. Mutant p53 gain-of-function induces 
epithelial-mesenchymal transition through modulation of the miR- 130b-
ZEB1 axis. Oncogene. 2013;32(27):3286–3295.
 59. Stinson S, Lackner MR, Adai AT, et al. TRPS1 targeting by 
 miR-221/222 promotes the epithelial-to-mesenchymal transition in 
breast cancer. Sci Signal. 2011;4(177):ra41.
 60. Siemens H, Jackstadt R, Hünten S, et al. miR-34 and SNAIL form a 
double-negative feedback loop to regulate epithelial-mesenchymal 
transitions. Cell Cycle. 2011;10(24):4256–4271.
 61. Moes M, Le Béchec A, Crespo I, et al. A novel network integrating 
a miRNA-203/SNAI1 feedback loop which regulates epithelial to 
mesenchymal transition. PLoS One. 2012;7(4):e35440.
 62. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b 
 suppresses prostate cancer metastasis by regulating epithelial-
 mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5): 
1166–1173.
 63. Zhang J, Zhang H, Liu J, et al. miR-30 inhibits TGF-β1-induced 
epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. 
Biochem Biophys Res Commun. 2012;417(3):1100–1105.
 64. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 
in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1): 
19–36.
 65. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, 
Hammond SM. Extensive post-transcriptional regulation of microRNAs 
and its implications for cancer. Genes Dev. 2006;20(16):2202–2207.
 66. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. 
Transforming growth factor-beta employs HMGA2 to elicit epithelial-
mesenchymal transition. J Cell Biol. 2006;174(2):175–183.
 67. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 
maintains oncogenic RAS-induced epithelial-mesenchymal transition in 
human pancreatic cancer cells. Am J Pathol. 2009;174(3):854–868.
 68. Qi J, Rice SJ, Salzberg AC, et al. MiR-365 regulates lung cancer 
and developmental gene thyroid transcription factor 1. Cell Cycle. 
2012;11(1):177–186.
 69. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity 
of breast cancer cells. Cell. 2007;131(6):1109–1123.
 70. Yun J, Frankenberger CA, Kuo WL, et al. Signalling pathway for RKIP 
and Let-7 regulates and predicts metastatic breast cancer. EMBO J. 
2011;30(21):4500–4514.
 71. Liu YN, Yin JJ, Abou-Kheir W, et al. MiR-1 and miR-200 inhibit 
EMT via Slug-dependent and tumorigenesis via Slug-independent 
mechanisms. Oncogene. 2013;32(3):296–306.
 72. Wang FE, Zhang C, Maminishkis A, et al. MicroRNA-204/211 alters 
epithelial physiology. FASEB J. 2010;24(5):1552–1571.
 73. Zhang Z, Zhang B, Li W, et al. Epigenetic Silencing of miR-203 
Upregulates SNAI2 and Contributes to the Invasiveness of Malignant 
Breast Cancer Cells. Genes Cancer. 2011;2(8):782–791.
 74. Liu YN, Abou-Kheir W, Yin JJ, et al. Critical and reciprocal  regulation 
of KLF4 and SLUG in transforming growth factor β-initiated prostate 
cancer epithelial-mesenchymal transition. Mol Cell Biol. 2012;32(5): 
941–953.
 75. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, Yang J. 
Snail2 is an essential mediator of Twist1-induced epithelial mesen-
chymal transition and metastasis. Cancer Res. 2011;71(1):245–254.
 76. Cubillo E, Diaz-Lopez A, Cuevas EP, et al. E47 and Id1 interplay in 
epithelial-mesenchymal transition. PLoS One. 2013;8(3):e59948.
 77. Dave N, Guaita-Esteruelas S, Gutarra S, et al. Functional cooperation 
between Snail1 and twist in the regulation of ZEB1 expression during 
epithelial to mesenchymal transition. J Biol Chem. 2011;286(14): 
12024–12032.
 78. Sobrado VR, Moreno-Bueno G, Cubillo E, et al. The class I bHLH 
factors E2-2A and E2-2B regulate EMT. J Cell Sci. 2009;122(Pt 7): 
1014–1024.
 79. Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human 
microRNAs that suppress breast cancer metastasis. Nature. 
2008;451(7175):147–152.
 80. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon 
that mediates endothelial recruitment and metastasis by cancer cells. 
Nature. 2012;481(7380):190–194.
 81. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA.  Concurrent 
suppression of integrin alpha5, radixin, and RhoA phenocopies the effects 
of miR-31 on metastasis. Cancer Res. 2010;70(12):5147–5154.
 82. Valastyan S, Weinberg RA. miR-31: a crucial overseer of tumor metas-
tasis and other emerging roles. Cell Cycle. 2010;9(11):2124–2129.
 83. Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res. 
2010;12(5):210.
 84. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and 
metastasis initiated by microRNA-10b in breast cancer. Nature. 
2007;449(7163):682–688.
 85. Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b 
modulates epithelial-mesenchymal transition by targeting TWIST1 
in invasive endometrial cancer cell lines. Mol Carcinog. Epub 
 September 3, 2013.
 86. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 
and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 
2008;10(2):202–210.
 87. Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c 
are downregulated in prostate cancer, suppress CD44 translation and 
enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol. 
2009;2(4):361–369.
 88. Pencheva N, Tran H, Buss C, et al. Convergent multi-miRNA target-
ing of ApoE drives LRP1/LRP8-dependent melanoma metastasis and 
angiogenesis. Cell. 2012;151(5):1068–1082.
 89. Gaziel-Sovran A, Segura MF, Di Micco R, et al. miR-30b/30d  regulation 
of GalNAc transferases enhances invasion and immunosuppression 
during metastasis. Cancer Cell. 2011;20(1):104–118.
 90. Kim NH, Kim HS, Li XY, et al. A p53/miRNA-34 axis regulates 
 Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell 
Biol. 2011;195(3):417–433.
 91. Jackstadt R, Röh S, Neumann J, et al. AP4 is a mediator of epithelial-
mesenchymal transition and metastasis in colorectal cancer. J Exp Med. 
2013;210(7):1331–1350.
 92. Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. 
 p53-Induced miR-15a/16-1 and AP4 Form a Double-Negative Feedback 
Loop to Regulate Epithelial-Mesenchymal Transition and Metastasis 
in Colorectal Cancer. Cancer Res. 2014;74(2):532–542.
 93. Ren D, Wang M, Guo W, et al. Wild-type p53 suppresses the epithelial-
mesenchymal transition and stemness in PC-3 prostate cancer cells by 
modulating miR145. Int J Oncol. 2013;42(4):1473–1481.
 94. Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactiva-
tion of miR-34a and miR-34b/c by CpG methylation in colorectal, 
pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas 
and soft tissue sarcomas. Virchows Arch. 2011;458(3):313–322.
 95. Davalos V, Moutinho C, Villanueva A, et al. Dynamic epigenetic 
regulation of the microRNA-200 family mediates epithelial and mes-
enchymal transitions in human tumorigenesis. Oncogene. 2012;31(16): 
2062–2074.
 96. Wee EJ, Peters K, Nair SS, et al. Mapping the regulatory sequences 
controlling 93 breast cancer-associated miRNA genes leads to the identi-
fication of two functional promoters of the Hsa-mir-200b cluster, methy-
lation of which is associated with metastasis or hormone receptor status 
in advanced breast cancer. Oncogene. 2012;31(38):4182–4195.
Cancer Management and Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/cancer-management-and-research-journal
Cancer Management and Research is an international, peer-reviewed 
open access journal focusing on cancer research and the optimal use of 
preventative and integrated treatment interventions to achieve improved 
outcomes, enhanced survival and quality of life for the cancer patient. 
The journal welcomes original research, clinical & epidemiological 
studies, reviews & evaluations, guidelines, expert opinion & commen-
tary, case reports & extended reports. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Cancer Management and Research 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
216
Díaz-López et al
 97. Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting dicer 
for metastasis control. Cell. 2010;141(7):1195–1207.
 98. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer 
associated with poor prognosis in lung cancer patients. Cancer Sci. 
2005;96(2):111–115.
 99. Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G. 
 Down-regulation of dicer expression in ovarian cancer tissues. Clin 
Biochem. 2010;43(3):324–327.
 100. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. 
Modulation of microRNA processing by p53. Nature. 2009;460(7254): 
529–533.
 101. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as 
stable blood-based markers for cancer detection. Proc Natl Acad Sci 
U S A. 2008;105(30):10513–10518.
 102. Ng EK, Wong CL, Ma ES, Kwong A. MicroRNAs as New Players 
for Diagnosis, Prognosis, and Therapeutic Targets in Breast Cancer. 
J Oncol. 2009;2009:305420.
 103. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma  microRNAs 
are promising novel biomarkers for early detection of colorectal cancer. 
Int J Cancer. 2010;127(1):118–126.
 104. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. 
 Circulating microRNAs as blood-based markers for patients with 
primary and metastatic breast cancer. Breast Cancer Res. 2010; 
12(6):R90.
 105. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression pro-
files associated with prognosis and therapeutic outcome in colon 
 adenocarcinoma. JAMA. 2008;299(4):425–436.
 106. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 Is induced by 
hypoxia and is an independent prognostic factor in breast cancer. Clin 
Cancer Res. 2008;14(5):1340–1348.
 107. Fu X, Han Y, Wu Y, et al. Prognostic role of microRNA-21 in various 
carcinomas: a systematic review and meta-analysis. Eur J Clin Invest. 
2011;41(11):1245–1253.
 108. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: 
rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10): 
775–789.
 109. Huynh C, Segura MF, Gaziel-Sovran A, et al. Efficient in vivo 
microRNA targeting of liver metastasis. Oncogene. 2011;30(12): 
1481–1488.
 110. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. 
microRNAs in cancer management. Lancet Oncol. 2012;13(6): 
e249–e258.
 111. Mei M, Ren Y, Zhou X, et al. Downregulation of miR-21 enhances 
chemotherapeutic effect of taxol in breast carcinoma cells. Technol 
Cancer Res Treat. 2010;9(1):77–86.
 112. Iorio MV, Casalini P, Piovan C, et al. microRNA-205 regulates HER3 
in human breast cancer. Cancer Res. 2009;69(6):2195–2200.
113. Chen D, Sun Y, Wei Y, et al. LIFR is a breast cancer metastasis sup-
pressor upstream of the Hippo-YAP pathway and a prognostic marker. 
Nat Med. 2012;18(10):1511–1517.
114. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses 
metastasis and modulates the tumour microenvironment by regulating 
microRNA-29b expression. Nat Cell Biol. 2013;15(2):201–213.
115. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q. Next-generation sequencing 
of microRNAs for breast cancer detection. J Biomed Biotechnol. 
2011;2011:597145.
116. Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA-30a 
inhibits epithelial-to-mesenchymal transition by targeting Snai1 
and is downregulated in non-small cell lung cancer. Int J Cancer. 
2012;130(9):2044–2053.
117. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate 
cancer stem cells and metastasis by directly repressing CD44. Nat 
Med. 2011;17(2):211–215.
118. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 
is a novel biomarker for metastatic colon cancer and predicts poor 
prognosis. PLoS One. 2011;6(3):e17745.
119. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency 
genomic alterations in human cancer. Proc Natl Acad Sci U S A. 
2006;103(24):9136–9141.
120. Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelial- 
mesenchymal transition through microRNAs targeting ZEB1 and 
ZEB2. J Exp Med. 2011;208(5):875–883.
121. Saini S, Majid S, Yamamura S, et al. Regulatory Role of mir-203 
in Prostate Cancer Progression and Metastasis. Clin Cancer Res. 
2011;17(16):5287–5298.
122. Matsushima K, Isomoto H, Yamaguchi N, et al. MiRNA-205 modulates 
cellular invasion and migration via regulating zinc finger E-box binding 
homeobox 2 expression in esophageal squamous cell carcinoma cells. 
J Transl Med. 2011;9:30.
123. Romero-Pérez L, Castilla MÁ, López-García MÁ, et al. Molecular 
events in endometrial carcinosarcomas and the role of high mobil-
ity group AT-hook 2 in endometrial carcinogenesis. Hum Pathol. 
2013;44(2):244–254.
